Glycogen storage disease type IV, amylopectinosis.
نویسندگان
چکیده
Classification of the glycogen storage diseases according to the underlying enzyme defect has added considerably to our understanding of this group of diseases. Of the 6 types in which the biochemical abnormality has been characterized, the least common appears to be type IV, amylopectin-osis. The first case was described by Andersen in 1952, and the glycogen present in the liver and other organs was shown by Illingworth and Cori (1952) to possess abnormally long outer and inner chains of glucose units. For this reason, Cori (1954) suggested that the enzyme, oc-1,4-glucan: oc-1,4 glucan 6-glycosyl transferase, effective in transferring chains of glucose units to form new branches in the glycogen molecule, was absent. Despite this clear recognition of a new syndrome, few cases have since been reported. A second was diagnosed during life by Sidbury et al. in 1962, and a brief account of a third, also diagnosed in life, was given 3 years later (Mortimer, 1965). Since then, descriptions of 3 more have appeared, 2 of whom were sibs (Holleman, van der Haar, and de Vaan, 1966; Brown and Brown, 1966; Fernandes and Huijing, 1968). In the last 2, absence or gross deficiency of the branching enzyme was conclusively demonstrated by assay. The present article is concerned with the third case to be reported, of which only preliminary details have previously been given (Mortimer, 1965). Glycogen storage disease was suspected at 8 months of age because of gross hepatomegaly associated with enlargement of the spleen. Investigations of carbohydrate metabolism supported the diagnosis, which was confirmed by an examination of a biopsy specimen of liver. The sparing solu-bility in water of the glycogen extracted from the liver, and the blue colour of its complex with iodine suggested an amylopectin-like structure, which was proved by a more complete examination. at term in hospital on March 4, 1964, after a normal pregnancy and delivery, birthweight 3515 g. For the first 5 weeks he was breast-fed, with dried milk supplements , but thereafter he was fully artificially fed. He gained weight satisfactorily till he was 6 months old, when he began to vomit and ceased to gain. At 8 months of age, he was admitted to hospital because of anorexia as well as persistent vomiting occurring at least once every day. He was then noted to be an alert and active, but wasted child, his weight being on the 3rd centile. The liver, which …
منابع مشابه
Amylopectinosis disease isolated to the heart with normal glycogen branching enzyme activity and gene sequence.
We report a 17-month-old female patient with a rare cause of cardiomyopathy secondary to accumulation of amylopectin-like material (fibrillar glycogen) isolated to the heart. Evidence of amylopectinosis isolated to cardiac myocytes in this patient was demonstrated by histology and electron microscopy. Glycogen content, glycogen branching enzyme (GBE) activity, as well as phosphofructokinase enz...
متن کاملBranching enzyme-deficiency glycogenosis: studies in therapy.
Type IV glycogen storage disease is caused by a deficiency of the branching enzyme, oc-1,4-glucan: ox-1,4-glucan 6-glucosyltransferase, EC 2.4.1.18 (Brown and Brown, 1966); and is characterized by the accumulation in liver, spleen, and other organs of glycogen with an abnormal structure. This glycogen has long outer chains, relatively few branch points, and gives a blue colour with iodine. It t...
متن کاملLiver transplantation for type IV glycogen storage disease.
T YPE IV glycogen storage disease is a rare autosomal recessive disorder (also called Andersen's diseasel or amylopectinosis) in which the activity of branching enzyme alpha-I, 4-g1ucan: alpha-I, 4-g1ucan 6-g1ucosyltransferase is deficient in the liver as well as in cultured skin fibroblasts and other tissues.2,3 This branching enzyme is responsible for creating branch points in the normal glyc...
متن کاملAlglucosidase alfa treatment alleviates liver disease in a mouse model of glycogen storage disease type IV
Patients with progressive hepatic form of GSD IV often die of liver failure in early childhood. We tested the feasibility of using recombinant human acid-α glucosidase (rhGAA) for treating GSD IV. Weekly intravenously injection of rhGAA at 40 mg/kg for 4 weeks significantly reduced hepatic glycogen accumulation, lowered liver/body weight ratio, and reduced plasma ALP and ALT activities in GSD I...
متن کاملHuman HOIP and LUBAC deficiency underlies autoinflammation, immunodeficiency, amylopectinosis, and lymphangiectasia
Inherited, complete deficiency of human HOIL-1, a component of the linear ubiquitination chain assembly complex (LUBAC), underlies autoinflammation, infections, and amylopectinosis. We report the clinical description and molecular analysis of a novel inherited disorder of the human LUBAC complex. A patient with multiorgan autoinflammation, combined immunodeficiency, subclinical amylopectinosis,...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Proceedings of the Royal Society of Medicine
دوره 61 12 شماره
صفحات -
تاریخ انتشار 1968